ACET ACET
Company Profile ↓Company Overview
ACET (ACET) is a publicly traded company listed on with a market capitalization of $87.81M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.09.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -16.79% |
| 6 Months: | +18.96% |
| 3 Months: | +7.64% |
| 1 Month: | +6.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 45.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.89M | 32.39M | 27.95M | 31.89M | 21.57M |
| Operating Income | -3.36M | -4.06M | -3.94M | -7.52M | -10.20M | -14.11M | -9.03M | -6.36M | -11.69M | -19.17M | -15.22M | -29.44M | -7.56M | -8.63M | -13.65M | -21.35M | -10.83M | -13.71M | 4.71M | -22.71M | -22.98M | -33.32M | -34.89M | -52.26M | -30.87M | -32.85M | -33.15M | - | -29.89M | -32.39M | -27.95M | -31.89M | -21.57M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.53M | -29.56M | -25.27M | -29.02M | -18.88M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 12.00K | 24.00K | 23.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.21M | -31.22M | -26.86M | -30.52M | -20.24M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | -3.36M | -4.06M | -3.31M | -23.05M | -9.86M | -13.59M | -8.41M | -5.76M | -4.13M | -2.65M | -14.78M | -28.89M | -4.49M | -8.46M | -14.78M | -21.32M | -10.85M | -14.01M | 4.62M | -22.54M | -22.00M | -30.88M | -32.40M | -49.88M | -28.02M | -29.90M | -30.48M | - | -28.21M | -31.22M | -26.86M | -30.52M | -20.24M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.82 | -0.34 | -0.44 | 0.10 | -0.56 | -0.53 | -0.72 | -0.75 | -1.16 | -0.35 | -0.33 | -0.34 | - | -4.96 | -5.44 | -4.64 | -2.94 | -1.88 |
| R&D Expense | 3.29M | 3.42M | 3.33M | - | 8.11M | 11.85M | 6.76M | - | 8.85M | 16.55M | 6.33M | - | 7.03M | 8.68M | 8.94M | 11.74M | 10.62M | 11.93M | 13.48M | 16.18M | 16.57M | 26.76M | 28.36M | 26.17M | 23.90M | 25.90M | 26.25M | - | 22.81M | 28.42M | 22.85M | - | 17.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 24.99M | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 97.54M | 132.58M | 127.61M | 122.11M |
| Operating Income | -18.88M | -14.96M | -31.39M | -39.19M | -61.43M | -72.55M | -132.58M | -127.61M | -122.11M |
| EBITDA | - | - | - | - | - | -67.14M | -136.53M | -110.65M | -110.39M |
| Interest Expense | - | - | - | - | - | 80.00K | 25.00K | 4.00K | 36.00K |
| Pretax Income | - | - | - | - | - | -69.79M | -142.66M | -117.12M | -116.80M |
| Tax Provision | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Net Income | -33.78M | -9.30M | -28.14M | -36.68M | -62.00M | -69.79M | -142.66M | -117.12M | -116.80M |
| Diluted EPS | - | - | - | - | -2.00 | -27.20 | -52.96 | -21.28 | -16.95 |
| R&D Expense | 16.84M | 14.72M | 23.69M | 34.33M | 48.94M | 71.25M | 106.04M | 99.32M | 99.13M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 55.19M | 109.94M | 81.59M | 153.84M | - | 330.69M | 207.29M | 220.22M | 192.35M |
| Current Assets | - | - | - | - | - | - | - | 261.04M | 162.27M | 180.14M | 160.93M |
| Cash & Equivalents | 0 | 0 | 53.35M | 9.47M | 10.61M | 84.33M | - | 257.66M | 159.71M | 56.49M | 38.92M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 185.00K | 0 | - | - | - |
| Total Liabilities | - | - | 5.50M | 5.74M | 27.87M | 44.01M | - | 38.35M | 37.12M | 33.61M | 33.15M |
| Current Liabilities | - | - | 5.50M | 5.72M | 14.87M | 22.48M | - | 19.71M | 19.29M | 19.39M | 21.53M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | 21.02M | 20.92M | 17.23M | 14.74M |
| Total Equity | 0 | 0 | -26.95M | -33.52M | -60.37M | 109.83M | - | 292.34M | 170.18M | 186.61M | 159.21M |
| Shares Outstanding | - | - | - | - | - | - | - | 2.68M | 2.70M | 5.16M | 9.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.98M | -18.18M | -27.88M | -41.55M | - | -44.77M | -93.72M | -92.38M | -95.25M |
| Investing Cash Flow | -44.00K | -16.06M | -47.93M | 115.22M | - | -16.78M | -4.46M | -119.24M | 2.39M |
| Financing Cash Flow | 64.38M | 11.05M | 76.94M | 303.00K | - | 41.51M | 236.00K | 111.31M | 75.25M |
| Capital Expenditure | -44.00K | -876.00K | -1.07M | -990.00K | - | -16.78M | -4.46M | -1.12M | -1.74M |
| Free Cash Flow | -11.03M | -19.06M | -28.95M | -42.54M | - | -61.55M | -98.18M | -93.50M | -96.98M |
| Net Change in Cash | - | - | - | - | - | -20.04M | -97.94M | -100.31M | -17.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -290.3% | - | - | - |
| Net Margin % | - | - | - | - | - | -279.3% | - | - | - |
| ROE % | 125.3% | 27.7% | 46.6% | -33.4% | - | -23.9% | -83.8% | -62.8% | -73.4% |
| ROCE % | -38.0% | -14.4% | -47.0% | -29.8% | - | -23.3% | -70.5% | -63.5% | -71.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ACET
Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 21, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Sc…
Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Harbour BioMed Appoints Dr. Lloyd Klickstein as Scientific Advisor for Immunology
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced the appointment of Dr…
Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference
Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company’s focus on …
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
REDWOOD CITY, Calif., August 05, 2026--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial r…
ACET — Frequently Asked Questions
What is the current share price of ACET?
As of 2026-08-05 17:25 PDT, ACET trades at $9.16 on NASDAQ/NYSE. Its 52-week range is $6.11 to $16.64.
What is the market capitalisation of ACET?
ACET has a market capitalisation of $87.81M on NASDAQ/NYSE.
What is the P/E ratio of ACET?
ACET trades at a trailing price-to-earnings (P/E) ratio of -0.54. Its price-to-book (P/B) ratio is 0.55.
What is the return on equity (ROE) of ACET?
ACET has a return on equity (ROE) of -73.36%. Its return on capital employed (ROCE) is -71.49%.
Is ACET a good stock to buy?
This page provides a data-driven analysis of ACET, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.